This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Inspira Stock to Gain From its Appearance at Annual ELSO Conference
by Zacks Equity Research
At the 34th annual ELSO conference in Detroit, IINN will present its FDA-cleared latest and future technology, the INSPIRA ART100 system.
IINN Stock Gains on Second US Patent Approval for VORTX System
by Zacks Equity Research
Inspira secures a second U.S. Patent approval for the VORTX orbiting blood oxygenation delivery system.
Favorable Clinical Results for HYLA Sensor Might Boost Inspira Stock
by Zacks Equity Research
IINN plans to report clinical results for its new HYLA blood sensor in open-heart surgery patients in the fourth quarter of 2024.
INSPIRA (IINN) CART Gets FDA Listing, to Enhance Healthcare
by Zacks Equity Research
Inspira (IINN) announces FDA listing of its INSPIRA CART, designed for use with the ART100 system, enhancing healthcare delivery during cardiopulmonary bypass.
Inspira (IINN) Unveils Business Targets for 2024-25
by Zacks Equity Research
Inspira (IINN) discloses business goals for 2024-25 with the rapid promotion of INSPIRA ART100 and the development of INSPIRA ART (Gen 2).
Inspira Technologies' (IINN) ART100 Gets FDA 510(k) Grant
by Zacks Equity Research
Inspira Technologies' (IINN) ART100 recent approval highlights the company's innovative advancements in medical technology.
Inspira Technologies (IINN) Strives to Get AMAR Nod for ART100
by Zacks Equity Research
The AMAR submission is a strategic move by Inspira Technologies (IINN), positioning it to target global markets with its innovative Augmented Respiration Technology (INSPIRA ART).
Inspira Technologies (IINN) Releases Favorable Data on VORTX
by Zacks Equity Research
Inspira Technologies' (IINN) proprietary orbiting oxygenation technology eliminates the need for membrane fibers, thereby reducing pressure differentials and high shear stress.
Inspira (IINN) Expands in Life Support Space With New Deal
by Zacks Equity Research
According to Inspira (IINN), the integration of its technology to oxygenate blood combined with Ennocure's infection prevention solutions is likely to help improve patient outcomes in ICUs.
Inspira (IINN) Advances Foothold in Europe With Extended Deal
by Zacks Equity Research
The extended service agreement complements a previously announced strategic agreement between Inspira (IINN) and Innovimed.